ATHX

Athersys, Inc. Common Stock
ATHX

Delisted

ATHX was delisted on the 26th of August, 2022.

Back to rankings
 

About: Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Employees: 104

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral
Business Wire
1 year ago
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating.
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
See News Rankings
Charts implemented using Lightweight Charts™